Navigation Links
Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial
Date:3/25/2009

CALGARY, March 25 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY) today announced the completion of patient enrolment in its U.K. clinical trial to evaluate the anti-tumour effects of intravenous administration of REOLYSIN(R) in combination with gemcitabine (Gemzar(R)) in patients with advanced cancers including breast, and head and neck. The principal investigators are Dr. Johann de Bono of The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, U.K., and Professor Jeff Evans of the University of Glasgow, Scotland.

A total of 15 patients were enrolled in the trial. Of the ten patients evaluable for response, two patients (breast and nasopharyngeal) had partial responses (PRs) and five patients had SD (stable disease) for 4-8 cycles, for a total disease control rate (CR (Complete response)+PR +SD) of 70%.

"The results to date using this treatment combination in late-stage cancer patients indicate that further studies using this drug combination are warranted," said Dr. Brad Thompson, President and CEO of Oncolytics. "We plan to initiate further studies in the U.S. using a modified dosage regime of REOLYSIN and the commonly used U.S. dosage of gemcitabine (800 mg/m(2)) in patients with advanced or metastatic pancreatic cancer in partnership with the Cancer Therapy & Research Center at The University of Texas Health Science Center in San Antonio, (CTRC at UTHSCSA)."

The U.K. trial (REO 009) is an open-label, dose-escalating, non-randomized study of REOLYSIN given intravenously with gemcitabine every three weeks. Gemcitabine (1000 mg/m(2)) was administered to patients in combination with escalating dosages of REOLYSIN intravenously.

Eligible patients included those who had been diagnosed with advanced or metastatic solid tumours including pancreatic, l
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech(R) Inc. Collaborators Present Reovirus Research at Replicating Oncolytic Virus Meeting
2. Oncolytics Biotech(R) Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Trial
3. Oncolytics Biotech(R) Inc. Collaborators Update Combination REOLYSIN(R) and Docetaxel Trial Results at Replicating Oncolytic Virus Meeting
4. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at AACR Annual Meeting
5. Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008
6. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioPartnering North America
7. Oncolytics Biotech Inc. Announces Issuance of 31st U.S. Patent
8. Oncolytics Biotech Inc.s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study
9. Media Advisory - Oncolytics Biotech Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference
10. Oncolytics Biotech Inc. Investigators Present Interim U.S. REOLYSIN(R) Phase II Sarcoma Trial Data
11. Oncolytics Biotech Inc. Announces U.S. Phase II Sarcoma Clinical Trial Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... ... 2015 , ... Cuvettes have been used in countless labs for decades. In the past, ... needed. As expected, this was a daunting and tiring process looking at endless data ... not able to navigate the complex catalog structure. , Now thanks to FireflySci, scientists are ...
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... Sleepless nights ... an individual’s quality of sleep, launched its Indiegogo campaign on June 23. Sound sleepers ... voice command technology makes it effortless to use, while the integration of the Bluetooth ...
(Date:7/1/2015)... July 1, 2015   Decision Resources Group ... advantages of Otezla are its oral administration, alternative ... reported by surveyed rheumatologists. Otezla was the first ... treatment of active psoriatic arthritis in ... of care includes conventional oral treatments including disease-modifying ...
(Date:7/1/2015)... , July 1, 2015  Axovant Sciences ... focused on the treatment of dementia, today announced ... on July 22 at 5:45 p.m. EDT following ... Alzheimer,s Association International Conference 2015 (AAIC). ... , Dr. Lawrence Friedhoff , ...
Breaking Biology Technology:New Cuvette E-Commerce Website Launched by FireflySci 2Luzi Smart Lamp Recently Launched Indiegogo Campaign 2Luzi Smart Lamp Recently Launched Indiegogo Campaign 3Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3
... ... of the prestigious eHealthcare Leadership Award given annually to organizations representing the best web ... ... leading provider of clinical trials information, received its fifth consecutive eHealthcare Leadership Award and ...
... GUANGZHOU, China, Nov. 11 /PRNewswire-Asia/ -- China ... "the Company"), a leading,developer and distributor of prescription ... nutritional and dietary supplements, and,medical devices and medical ... call at 10:00 a.m. Eastern Time on Monday, ...
... Pa., Nov. 9 /PRNewswire-Asia-FirstCall/ -- BMP Sunstone,Corporation (Nasdaq: BJGP ) ... quarter ended September 30, 2009. , , Third ... to $33.6 million from $30.5 million in the prior year, ... particularly in, licensed products;, ...
Cached Biology Technology:CenterWatch Honored a Fifth Consecutive Year for Best Healthcare Content 2China Medicine Announces Conference Call to Discuss Third Quarter 2009 Results 2China Medicine Announces Conference Call to Discuss Third Quarter 2009 Results 3BMP Sunstone Reports Third Quarter 2009 Financial Results 2BMP Sunstone Reports Third Quarter 2009 Financial Results 3BMP Sunstone Reports Third Quarter 2009 Financial Results 4BMP Sunstone Reports Third Quarter 2009 Financial Results 5BMP Sunstone Reports Third Quarter 2009 Financial Results 6BMP Sunstone Reports Third Quarter 2009 Financial Results 7BMP Sunstone Reports Third Quarter 2009 Financial Results 8BMP Sunstone Reports Third Quarter 2009 Financial Results 9BMP Sunstone Reports Third Quarter 2009 Financial Results 10BMP Sunstone Reports Third Quarter 2009 Financial Results 11BMP Sunstone Reports Third Quarter 2009 Financial Results 12
(Date:6/16/2015)... June 16, 2015 /CNW Telbec/ - handyem Inc. ... around the incorporation of handyem,s HPC-150 portable flow ... the Mo-POD™. This unprecedented model of mobile laboratory ... at the Pennsylvania Convention ... 15 th to 18 th 2015. ...
(Date:6/16/2015)... , June 16, 2015 Fingerprint ... previously communicated that it will amount to at least 340 ... Due to the rapid increase in market growth and orders ... previously communicated guidance that revenue for 2015 will exceed 1,500 ... amount to approximately 2,200 MSEK. Due to receipt ...
(Date:6/15/2015)... , Jun. 15, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... on the growing mobile commerce market, announces that its leading ... to media at Digital Experience! @ NYC June 18th. ... of the latest innovation in technology to over 300 of ... held at the Metropolitan Pavilion in New York ...
Breaking Biology News(10 mins):handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 2Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 3
... Systemic scleroderma has slowed Tracy Zinn but it has not ... an accommodating employer, Zinn is now in her 13th year ... software. But, many with the incapacitating disease are not as ... for people with systemic scleroderma, also known as systemic sclerosis, ...
... Biological Studies announced today that they are renewing the ... mission of the partnership is to advance knowledge in ... and applied biology research. The Ipsen Life Sciences ... Irwin and Joan Jacobs Chair in Exemplary Science will ...
... new map of the potato genome that may lead ... help feed the world,s hungry. By sequencing and ... consortium has, for the first time, tied specific potato ... and development of potatoes may enable scientists and breeders ...
Cached Biology News:Scleroderma study identifies roadblocks to employment 2Scleroderma study identifies roadblocks to employment 3Renewal of agreement between Ipsen and the Salk Institute supports cutting-edge research 2
... EPS 301 Power Supply, 1. ... maximum.Constant voltage or constant current modes.Single-unit ... precision and reproducibility.Suitable for submarine, mini ... as well as semidry and mini ...
... Supply, 1. 1000 V, 400 mA, ... and constant power modes.Single-unit increments in ... reproducibility.Stores and recalls three protocols.Outstanding choice ... Multiphor II or GenePhor systems. ...
Mouse TrkC Affinity Purified Polyclonal Ab...
Immunogen: Full length M32 fusion protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: